Go to
JCI Insight
Citations to this article
A Redlitz, … , D L Eaton, E F Plow
Published November 1, 1995
Citation Information: J Clin Invest. 1995;96(5):2534-2538. https://doi.org/10.1172/JCI118315.
Citation Information: J Clin Invest. 1995;96(5):2534-2538. https://doi.org/10.1172/JCI118315.
Abstract
Authors
A Redlitz, A K Tan, D L Eaton, E F Plow
Total citations by year
Citation information
Citations to this article (174)
| Title and authors | Publication | Year |
|---|---|---|
|
Molecular Characterization, Recombinant Expression, and Functional Analysis of Carboxypeptidase B in Litopenaeus vannamei
Li H, Lin H, Yang H, Ren C, He Y, Jiang X, Chen T, Hu C |
Genes | 2025 |
|
Droplet microfluidic screening to engineer angiotensin-converting enzyme 2 (ACE2) catalytic activity
Okal EF, Romero PA, Heinzelman P |
Journal of Biological Engineering | 2025 |
|
Hereditary angioedema with normal C1 inhibitor associated with carboxypeptidase N deficiency
Vincent D, Parsopoulou F, Martin L, Gaboriaud C, Demongeot J, Loules G, Fischer S, Cichon S, Germenis AE, Ghannam A, Drouet C |
2024 | |
|
Identification of heparin interaction sites on thrombin-activatable fibrinolysis inhibitor that modulate plasmin-mediated activation, thermal stability, and antifibrinolytic potential
Marar TT, Boffa MB |
Research and Practice in Thrombosis and Haemostasis | 2024 |
|
Altered fibrinogen γ-chain cross-linking in mutant fibrinogen-γ(Δ5) mice drives acute liver injury.
Poole LG, Schmitt LR, Schulte A, Groeneveld DJ, Cline HM, Sang Y, Hur WS, Wolberg AS, Flick MJ, Hansen KC, Luyendyk JP |
Journal of Thrombosis and Haemostasis | 2023 |
|
Carboxypeptidase U (CPU, TAFIa, CPB2) in Thromboembolic Disease: What Do We Know Three Decades after Its Discovery?
K Claesen, JC Mertens, D Leenaerts, D Hendriks |
International journal of molecular sciences | 2021 |
|
Proteomics-Based Approach to Identify Novel Blood Biomarker Candidates for Differentiating Intracerebral Hemorrhage From Ischemic Stroke-A Pilot Study.
Malicek D, Wittig I, Luger S, Foerch C |
Frontiers in neurology | 2021 |
|
Serum Proteomic Changes as Candidate Biomarkers of Intermediate Liver Fibrosis in Chronic Hepatitis B Infection
YN Dai, YX Tu, D Meng, MJ Chen, JJ Zhang, YH Gong, YX Tong, MS Wang, HY Pan, HJ Huang |
Omics A Journal of Integrative Biology | 2019 |
|
Effects of Plasmin on von Willebrand Factor and Platelets: A Narrative Review
L van der Vorm, J Remijn, B de Laat, D Huskens |
TH Open | 2018 |
|
Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment
ZA Bazzi, J Balun, D Cavallo-Medved, LA Porter, MB Boffa |
Clinical & Experimental Metastasis | 2017 |
|
Suppression of TAFI by siRNA inhibits invasion and migration of breast cancer cells
C Yu, Y Luan, Z Wang, J Zhao, C Xu |
Molecular medicine reports | 2017 |
|
Activated thrombin-activatable fibrinolysis inhibitor (TAFIa) attenuates breast cancer cell metastatic behaviors through inhibition of plasminogen activation and extracellular proteolysis
ZA Bazzi, D Lanoue, M El-Youssef, R Romagnuolo, J Tubman, D Cavallo-Medved, LA Porter, MB Boffa |
BMC Cancer | 2016 |
|
Cellular and molecular mechanisms of acute exposure to sulfur mustard: a systematic review
MR Nourani, HM Hosseini, SA Jamalkandi, AA Fooladi |
Journal of Receptors and Signal Transduction | 2016 |
|
Discovery of anabaenopeptin 679 from freshwater algal bloom material: Insights into the structure–activity relationship of anabaenopeptin protease inhibitors
H Harms, KL Kurita, L Pan, PG Wahome, H He, AD Kinghorn, GT Carter, RG Linington |
Bioorganic & Medicinal Chemistry Letters | 2016 |
|
Trauma Induced Coagulopathy
E Gonzalez, HB Moore, EE Moore |
2016 | |
|
Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis
K Qian, J Xu, H Wan, F Fu, J Lu, Z Lin, Z Liu, H Liu |
Gene | 2015 |
|
Impact of dabigatran on platelet function and fibrinolysis
AE Tsantes, E Kyriakou, S Bonovas, M Chondrogianni, C Zompola, C Liantinioti, A Simitsi, AH Katsanos, M Atta, I Ikonomidis, V Kapsimali, P Kopterides, G Tsivgoulis |
Journal of the Neurological Sciences | 2015 |
|
PI3-Kinase Inhibitor LY294002 Repressed the Expression of Thrombin-Activatable Fibrinolysis Inhibitor in Human Hepatoma HepG2 Cells
Y Masuda, J Yazawa, Y Makino, K Takada |
Biological & Pharmaceutical Bulletin | 2015 |
|
Antifibrinolytic Mechanisms in Acute Airway Injury after Sulfur Mustard Analog Inhalation
RC Rancourt, A Ahmad, LA Veress, JS Rioux, RB Garlick, CW White |
American journal of respiratory cell and molecular biology | 2014 |
|
A plasmin-activatable thrombin inhibitor reduces experimental thrombosis and assists experimental thrombolysis in murine models
WP Sheffield, LJ Eltringham-Smith, S Gataiance, V Bhakta |
Journal of Thrombosis and Thrombolysis | 2014 |
|
Inhibition of thrombin-activated fibrinolysis inhibitor decreases postoperative adhesion
TH Kim, JS Park, SS An, H Kang |
Journal of Surgical Research | 2014 |
|
Laboratory Assessment of the Anticoagulant Activity of Dabigatran
E Kyriakou, I Ikonomidis, D Stylos, S Bonovas, I Papadakis, GK Nikolopoulos, S Kokoris, D Kalantzis, C Economopoulou, P Kopterides, J Lekakis, AE Tsantes |
Clinical and Applied Thrombosis/Hemostasis | 2014 |
|
Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin
A Kovács, L Szabó, C Longstaff, K Tenekedjiev, R Machovich, K Kolev |
Thrombosis Research | 2013 |
|
Handbook of Proteolytic Enzymes
FS Markland, S Swenson |
Handbook of Proteolytic Enzymes | 2013 |
|
Insights into thrombin activatable fibrinolysis inhibitor function and regulation
JH Foley, PY Kim, NJ Mutch, A Gils |
Journal of Thrombosis and Haemostasis | 2013 |
|
Arginine and lysine as products of basic carboxypeptidase activity associated with fibrinolysis
AA Zhloba, TF Subbotina, DS Lupan, VA Bogova, OA Kusheleva |
Biomeditsinskaya Khimiya | 2013 |
|
Natural and Engineered Plasmin Inhibitors: Applications and Design Strategies
JE Swedberg, JM Harris |
ChemBioChem | 2012 |
|
Arginine and lysine as products of basic carboxypeptidase activity associated with fibrinolysis
AA Zhloba, TF Subbotina, DS Lupan, VA Bogova, OA Kusheleva |
Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry | 2012 |
|
Identification of host genes showing differential expression profiles with cell-based long-term replication of hepatitis C virus RNA
H Sejima, K Mori, Y Ariumi, M Ikeda, N Kato |
Virus Research | 2012 |
|
Intravenous and oral administrations of DD2 [7-Amino-2-(sulfanylmethyl)heptanoic acid] produce thrombolysis through inhibition of plasma TAFIa in rats with tissue factor-induced microthrombosis
T Sasaki, N Yoshimoto, K Sugimoto, K Takada, N Murayama, H Yamazaki, K Yamamoto, H Ishii |
Thrombosis Research | 2012 |
|
Dietary zinc depletion and repletion affects plasma proteins: an analysis of the plasma proteome
A Grider, K Wickwire, E Ho, CS Chung, J King |
BioMetals | 2012 |
|
Peroxisome proliferator-activated receptor-alpha agonists repress expression of thrombin-activatable fibrinolysis inhibitor by decreasing transcript stability:
Y Masuda, D Saotome, K Takada, K Sugimoto, T Sasaki, H Ishii |
Thrombosis and Haemostasis | 2012 |
|
Fibrinolytic system in preeclampsia
MB Pinheiro, KB Gomes, LM Dusse |
Clinica Chimica Acta | 2012 |
|
Alternative Mechanism of Aspirin in Anti-Thrombotic Therapy: Inhibition of Thrombin Activatable Fibrinolysis Inhibitor
SS An, RS Greenfield |
Bulletin of the Korean Chemical Society | 2012 |
|
Is there any role of thrombin activatable fibrinolysis inhibitor in the development of a hypercoagulable state in gastric cancer
M Eser, M Kement, S Balin, C Coskun, U Kefeli, M Gumus, YE Altuntas, N Kurt, A Mayadagli |
World journal of surgical oncology | 2012 |
|
Plasma carboxypeptidase B downregulates inflammatory responses in autoimmune arthritis
Jason Song, Inyong Hwang, Kyung Cho, Michael Garcia, Arthur Kim, Tiffany Wang, Tamsin Lindstrom, Annette Lee, Toshihiko Nishimura, Lei Zhao, John Morser, Michael Nesheim, Stuart Goodman, David Lee, Jr S. Louis Bridges, Peter K. Gregersen, Lawrence Leung, William Robinson |
Journal of Clinical Investigation | 2011 |
|
Advances in Protein Chemistry and Structural Biology
A Fortian, D Castaño, E Gonzalez, A Laín, JM Falcon-Perez, O Millet |
Protein Structure and Diseases | 2011 |
|
Thrombin-Activatable Fibrinolysis Inhibitor in Breast Cancer Patients
O Kaftan, B Kasapoglu, M Koroglu, A Kosar, SK Yalcin |
Medical Principles and Practice | 2011 |
|
Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms
N Mishra, E Vercauteren, J Develter, R Bammens, PJ Declerck, A Gils |
Thrombosis and Haemostasis | 2011 |
|
Recent Advances in Biochemistry
D Rotin |
Recent Advances in Biochemistry | 2011 |
|
Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1
ME Meltzer, T Lisman, PG de Groot, JC Meijers, S Cessie, CJ Doggen, FR Rosendaal |
Blood | 2010 |
|
Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis
R Park, J Song, SS An |
The Korean Journal of Hematology | 2010 |
|
Effect of obesity on TAFI in postmenopausal period
B Taskiran, S Guldiken, AM Demir, TK Okman, E Arikan, B Turgut, AA Tugrul |
Obesity Research & Clinical Practice | 2010 |
|
Procarboxypeptidase R Deficiency Causes Increased Lethality in Concanavalin A-Induced Hepatitis in Female Mice
S Asai, N Kimbara, T Tada, M Imai, W Campbell, H Okada, N Okada |
Biological & Pharmaceutical Bulletin | 2010 |
|
Angiogenesis
TH Adair, JP Montani |
Colloquium Series on Integrated Systems Physiology: From Molecule to Function | 2010 |
|
The Effect of the Acute Submaximal Exercise on Thrombin Activatable Fibrinolysis Inhibitor Levels in Young Sedentary Males
S Kahraman, CŞ Bediz, Ö Pişkin, İ Aksu, A Topçu, F Yüksel, F Demirkan |
Clinical and Applied Thrombosis/Hemostasis | 2010 |
|
Textbook of Pulmonary Vascular Disease
, JG Garcia, JB West, CA Hales, S Rich, SL Archer |
2010 | |
|
Biochemical characterization of bovine plasma thrombin-activatable fibrinolysis inhibitor (TAFI)
Z Valnickova, M Thaysen-Andersen, P Højrup, T Christensen, KW Sanggaard, T Kristensen, JJ Enghild |
BMC Biochemistry | 2009 |
|
A novel function of thrombin-activatable fibrinolysis inhibitor during rat liver regeneration and in growth-promoted hepatocytes in primary culture
N Okumura, T Koh, Y Hasebe, T Seki, T Ariga |
The Journal of biological chemistry | 2009 |
|
Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
JL Willemse, E Heylen, ME Nesheim, DF Hendriks |
Journal of Thrombosis and Haemostasis | 2009 |
|
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hyperthyroidism
C Erem, O Ucuncu, M Yilmaz, M Kocak, İ Nuhoglu, HO Ersoz |
Endocrine | 2009 |
|
Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels
C Erem, I Nuhoglu, M Yilmaz, M Kocak, A Demirel, O Ucuncu, HO Ersoz |
Journal of Endocrinological Investigation | 2009 |
|
Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism
C Erem, M Kocak, I Nuhoglu, M Yilmaz, O Ucuncu |
European Journal of Endocrinology | 2009 |
|
Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI
C Erem, İ Nuhoglu, M Kocak, M Yilmaz, ST Sipahi, O Ucuncu, HO Ersoz |
Endocrine | 2008 |
|
Regulation of tissue inflammation by thrombin-activatable carboxypeptidase B (or TAFI)
LL Leung, T Myles, T Nishimura, JJ Song, WH Robinson |
Molecular Immunology | 2008 |
|
Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism
C Erem, O Ucuncu, M Yilmaz, M Kocak, İ Nuhoglu, HO Ersoz |
Endocrine | 2008 |
|
Proteolytic cleavage of carboxypeptidase N markedly increases its antifibrinolytic activity
JB Walker, TM Binette, M Mackova, GR Lambkin, L Mitchell, L Bajzar |
Journal of Thrombosis and Haemostasis | 2008 |
|
The role of carboxypeptidases in carcinogenesis
IL Vovchuk, SA Petrov |
Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry | 2008 |
|
Regulation of Chemerin Bioactivity by Plasma Carboxypeptidase N, Carboxypeptidase B (Activated Thrombin-activable Fibrinolysis Inhibitor), and Platelets
XY Du, BA Zabel, T Myles, SJ Allen, TM Handel, PP Lee, EC Butcher, LL Leung |
The Journal of biological chemistry | 2008 |
|
Thrombin-activable Fibrinolysis Inhibitor Zymogen Does Not Play a Significant Role in the Attenuation of Fibrinolysis
JH Foley, P Kim, ME Nesheim |
The Journal of biological chemistry | 2008 |
|
Current Topics in Complement II
JD Lambris |
2008 | |
|
Histone H2B as a functionally important plasminogen receptor on macrophages
R Das, T Burke, EF Plow |
Blood | 2007 |
|
Impairment of the hemostatic potential of platelets during storage as evaluated by flow cytometry, thrombin generation, and thrombelastography under conditions promoting formation of coated platelets
MS Svendsen, R Rojkjaer, AT Kristensen, JA Salado-Jimena, M Kjalke, PI Johansson |
Transfusion | 2007 |
|
Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon
TM Binette, FB Taylor, G Peer, L Bajzar |
Blood | 2007 |
|
Structure and function of human plasma carboxypeptidase N, the anaphylatoxin inactivator
RA Skidgel, EG Erdös |
International Immunopharmacology | 2007 |
|
Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke
E Rooth, H Wallen, A Antovic, M Arbin, G Kaponides, N Wahlgren, M Blombäck, J Antovic |
Blood Coagulation & Fibrinolysis | 2007 |
|
TAFIa, PAI-1 and ?2-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots
NJ Mutch, L Thomas, NR Moore, KM Lisiak, NA Booth |
Journal of Thrombosis and Haemostasis | 2007 |
|
Seminal thrombin-activatable fibrinolysis inhibitor: a regulator of liquefaction
BA Lwaleed, A Goyal, RS Greenfield, AJ Cooper |
Blood Coagulation & Fibrinolysis | 2007 |
|
Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A
AM Hvas, HT Sørensen, L Norengaard, K Christiansen, J Ingerslev, B Sørensen |
Journal of Thrombosis and Haemostasis | 2007 |
|
Plasminogen binding and activation at the breast cancer cell surface: the integral role of urokinase activity
GE Stillfried, DN Saunders, M Ranson |
Breast Cancer Research | 2007 |
|
Clot Stabilization for the Prevention of Bleeding
LP Rojkjaer, R Rojkjaer |
Hematology/Oncology Clinics of North America | 2007 |
|
Curiouser and curiouser: Recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles
M Boffa, M Koschinsky |
Clinical Biochemistry | 2007 |
|
TAFIa, PAI-1 and ? 2 -antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots
NJ Mutch, L Thomas, NR Moore, KM Lisiak, NA Booth |
Journal of Thrombosis and Haemostasis | 2007 |
|
Crystal Structure of the Human Carboxypeptidase N (Kininase I) Catalytic Domain
C Keil, K Maskos, M Than, JT Hoopes, R Huber, F Tan, PA Deddish, EG Erdös, RA Skidgel, W Bode |
Journal of Molecular Biology | 2007 |
|
Thrombin activatable fibrinolysis inhibitor (TAFI): A role in pre-eclampsia?
LM Dusse, AJ Cooper, BA Lwaleed |
Clinica Chimica Acta | 2007 |
|
Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis
X Wang, PL Smith, MY Hsu, JA Tamasi, E Bird, WA Schumacher |
Journal of Thrombosis and Thrombolysis | 2006 |
|
Thrombin activatable fibrinolysis inhibitor (TAFI)—How does thrombin regulate fibrinolysis?
BN Bouma, LO Mosnier |
Annals of Medicine | 2006 |
|
Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo
T Nishimura, T Myles, AM Piliposky, PN Kao, GJ Berry, LL Leung |
Blood | 2006 |
|
Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis
W Knecht, J Willemse, H Stenhamre, M Andersson, P Berntsson, C Furebring, A Harrysson, AC Hager, BM Wissing, D Hendriks, P Cronet |
FEBS Journal | 2006 |
|
Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor
X Wang, PL Smith, MY Hsu, ML Ogletree, WA Schumacher |
Journal of Thrombosis and Haemostasis | 2006 |
|
Système du plasminogène et son exploration
J Lebrazi, MM Samama, F Bachmann |
EMC - Hematologie | 2006 |
|
Post-translational Modifications of Human Thrombin-Activatable Fibrinolysis Inhibitor (TAFI): Evidence for a Large Shift in the Isoelectric Point and Reduced Solubility upon Activation
Z Valnickova, T Christensen, P Skottrup, IB Thøgersen, P Højrup, JJ Enghild |
Biochemistry | 2006 |
|
Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice
SS Mao, MA Holahan, C Bailey, G Wu, D Colussi, SS Carroll, JJ Cook |
Blood Coagulation & Fibrinolysis | 2005 |
|
Molecular mechanisms of fibrinolysis
G Cesarman-Maus, KA Hajjar |
British Journal of Haematology | 2005 |
|
Normal Clotting
TA Moran, CS Viele |
Seminars in Oncology Nursing | 2005 |
|
Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N
MO Quagraine, F Tan, H Tamei, EG Erdös, RA Skidgel |
Biochemical Journal | 2005 |
|
A new functional assay of thrombin activatable fibrinolysis inhibitor
AH Guimarães, RM Bertina, DC Rijken |
Journal of Thrombosis and Haemostasis | 2005 |
|
High dose factor VIIa improves clot structure and stability in a model of haemophilia B
AS Wolberg, GA Allen, DM Monroe, U Hedner, HR Roberts, M Hoffman |
British Journal of Haematology | 2005 |
|
Inhibition of thrombin activatable fibrinolysis inhibitor augments fibrinolysis in human whole blood
NL Cruden, L Lawes, P Masson, SD Robinson, CA Ludlam, DE Newby |
Journal of Thrombosis and Haemostasis | 2005 |
|
Genetic basis of phenotypic plasticity for predator-induced morphological defenses in anuran tadpole, Rana pirica, using cDNA subtraction and microarray analysis
T Mori, I Hiraka, Y Kurata, H Kawachi, O Kishida, K Nishimura |
Biochemical and Biophysical Research Communications | 2005 |
|
Plasminogen interaction with platelets: The importance of carboxyterminal lysines
MD Horne, PK Merryman, AM Cullinane |
Thrombosis Research | 2005 |
|
Hepatitis Induced by an IgM Monoclonal Antibody against Procarboxypeptidase R
L He, S Asai, T Kawamura, N Kimbara, T Tada, H Okada, N Okada |
Microbiology and Immunology | 2005 |
|
Absence of Thrombin-Activatable Fibrinolysis Inhibitor Protects against Sepsis-Induced Liver Injury in Mice
R Renckens, JJ Roelofs, SA ter Horst, C van t Veer, SR Havik, S Florquin, GT Wagenaar, JC Meijers, T van der Poll |
Journal of immunology (Baltimore, Md. : 1950) | 2005 |
|
Crystal Structures of Potent Thiol-Based Inhibitors Bound to Carboxypeptidase B ,
M Adler, J Bryant, B Buckman, I Islam, B Larsen, S Finster, L Kent, K May, R Mohan, S Yuan, M Whitlow |
Biochemistry | 2005 |
|
Enhancement of Fibrinolysis by EF6265 [( S )-7-Amino-2-[[[( R )-2-methyl-1-(3-phenylpropanoylamino)propyl]hydroxyphosphinoyl] methyl]heptanoic Acid], a Specific Inhibitor of Plasma Carboxypeptidase B
K Suzuki, Y Muto, K Fushihara, K Kanemoto, H Iida, E Sato, C Kikuchi, T Matsushima, E Kato, M Nomoto, S Yoshioka, H Ishii |
The Journal of pharmacology and experimental therapeutics | 2004 |
|
Absence of Procarboxypeptidase R Induces Complement-Mediated Lethal Inflammation in Lipopolysaccharide-Primed Mice
S Asai, T Sato, T Tada, T Miyamoto, N Kimbara, N Motoyama, H Okada, N Okada |
Journal of immunology (Baltimore, Md. : 1950) | 2004 |
|
Fibrinogen binding potentiates FGF-2 but not VEGF induced expression of u-PA, u-PAR, and PAI-1 in endothelial cells
A Sahni, SK Sahni, PJ Simpson-Haidaris, CW Francis |
Journal of Thrombosis and Haemostasis | 2004 |
|
Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays
AH Guimaraes, NH Tilburg, HL Vos, RM Bertina, DC Rijken |
British Journal of Haematology | 2004 |
|
TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction
H Akatsu, H Yamagata, Y Chen, T Miki, K Kamino, M Takeda, W Campbell, I Kondo, K Kosaka, T Yamamoto, H Okada |
British Journal of Haematology | 2004 |
|
Mechanism of action of carboxypeptidase U: staying above the threshold
PF Marx, JC Meijers |
Journal of Thrombosis and Haemostasis | 2004 |
|
New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R)
BN Bouma, JC Meijers |
Seminars in Hematology | 2004 |
|
Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism
RE Schutgens, EU Esseboom, RJ Snijder, FJ Haas, F Verzijlbergen, HK Nieuwenhuis, T Lisman, DH Biesma |
Journal of Laboratory and Clinical Medicine | 2004 |
|
Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
JP Antovic, S Schulman, SS An, RS Greenfield, M Blombäck |
Scandinavian Journal of Clinical & Laboratory Investigation | 2004 |
|
Coagulation in sepsis
A Amaral, SM Opal, JL Vincent |
Intensive Care Medicine | 2004 |
|
Roles of factor XI, platelets and tissue factor-initiated blood coagulation
PN Walsh |
Journal of Thrombosis and Haemostasis | 2003 |
|
Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI
NJ Mutch, NR Moore, E Wang, NA Booth |
Journal of Thrombosis and Haemostasis | 2003 |
|
Recombinant factor VIIa reverses the in vitro and ex vivo anticoagulant and profibrinolytic effects of fondaparinux
T Lisman, NR Bijsterveld, J Adelmeijer, JC Meijers, M Levi, HK Nieuwenhuis, PG de Groot |
Journal of Thrombosis and Haemostasis | 2003 |
|
TAFI and wound healing: closing a knowledge gap
MB Boffa |
Journal of Thrombosis and Haemostasis | 2003 |
|
Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome
H Aubert, C Frere, MF Aillaud, PE Morange, I Juhan-Vague, MC Alessi |
Journal of Thrombosis and Haemostasis | 2003 |
|
Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)
BN Bouma, JC Meijers |
Journal of Thrombosis and Haemostasis | 2003 |
|
Thrombin Activatable Fibrinolysis Inhibitor (TAFI) at the Interface between Coagulation and Fibrinolysis
BN Bouma, LO Mosnier |
Pathophysiology of Haemostasis and Thrombosis | 2003 |
|
Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications
JP Antovic, M Yngen, CG ??stenson, A Antovic, HN Wallen, G Jornesk??g, M Blomb??ck |
Blood Coagulation & Fibrinolysis | 2003 |
|
Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats
Y Muto, K Suzuki, E Sato, H Ishii |
European Journal of Pharmacology | 2003 |
|
Preferential Detection of Pro-Carboxypeptidase R by Enzyme-Linked Immunosorbent Assay
S Tani, H Akatsu, Y Ishikawa, N Okada, H Okada |
Microbiology and Immunology | 2003 |
|
Mutations in the Substrate Binding Site of Thrombin-activatable Fibrinolysis Inhibitor (TAFI) Alter Its Substrate Specificity
L Zhao, B Buckman, M Seto, J Morser, M Nagashima |
The Journal of biological chemistry | 2003 |
|
Generation and Characterization of a Highly Stable Form of Activated Thrombin-activable Fibrinolysis Inhibitor
PF Marx, SR Havik, JA Marquart, BN Bouma, JC Meijers |
The Journal of biological chemistry | 2003 |
|
Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life
Mariko Nagashima, Zheng-Feng Yin, Lei Zhao, Kathy White,Yanhong Zhu, Nina Lasky, Meredith Halks-Miller, George J. Broze, Jr., William P. Fay, John Morser |
Journal of Clinical Investigation | 2002 |
|
In Vivo Regulation of the Functions of Plasminogen by Plasma Carboxypeptidase B
Carmen M. Swaisgood, Detlef Schmitt, Dan Eaton, Edward F. Plow |
Journal of Clinical Investigation | 2002 |
|
Antithrombotic agents in the treatment of severe sepsis
H Shadid, S Aziz, S Ahmad, J Fareed, D Hoppensteadt, H Messmore, W Wehrmacher, M Tobu, O Iqbal |
Expert Opinion on Emerging Drugs | 2002 |
|
The Role of Proteases in Fibronectin Matrix Remodeling in Thyroid Epithelial Cell Monolayer Cultures
L Nezi, D Greco, L Nitsch, C Garbi |
Biological Chemistry | 2002 |
|
Rational Structure-Based Design of a Novel Carboxypeptidase R Inhibitor
E Lazoura, W Campbell, Y Yamaguchi, K Kato, N Okada, H Okada |
Chemistry & Biology | 2002 |
|
Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation
JP Antovic, M Blombäck |
Thrombosis Research | 2002 |
|
Recombinant factor VIIa improves clot formation but not fibrolytic potential in patients with cirrhosis and during liver transplantation
T Lisman |
Hepatology | 2002 |
|
Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe
I Juhan-Vague, PE Morange, H Aubert, M Henry, MF Aillaud, MC Alessi, A Samnegård, E Hawe, J Yudkin, M Margaglione, GD Minno, A Hamsten, SE Humphries |
Arteriosclerosis, thrombosis, and vascular biology | 2002 |
|
Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A
T Lisman, LO Mosnier, T Lambert, EP Mauser-Bunschoten, JC Meijers, HK Nieuwenhuis, PG de Groot |
Blood | 2002 |
|
The p11 Subunit of Annexin II Heterotetramer Is Regulated by Basic Carboxypeptidase
DK Fogg, DE Bridges, KK Cheung, G Kassam, NR Filipenko, KS Choi, SL Fitzpatrick, M Nesheim, DM Waisman |
Biochemistry | 2002 |
|
Plasmin-Mediated Activation and Inactivation of Thrombin-Activatable Fibrinolysis Inhibitor
PF Marx, PE Dawson, BN Bouma, JC Meijers |
Biochemistry | 2002 |
|
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis
VV Kakkar, DA Hoppenstead, J Fareed, Z Kadziola, M Scully, R Nakov, HK Breddin |
Blood | 2002 |
|
Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A
J Antovic, S Schulman, A Eelde, M Blomback |
Haemophilia | 2001 |
|
Fast Homogeneous Assay for Plasma Procarboxypeptidase U
KA Schatteman, FJ Goossens, J Leurs, Y Kasahara, SS Scharpé, DF Hendriks |
Clinical Chemistry and Laboratory Medicine | 2001 |
|
Hyperphosphatemia in a Burn Patient
VD Bachelder, SG Muehlstedt, CL Smith |
Journal of Burn Care & Rehabilitation | 2001 |
|
Thrombin-Activatable Fibrinolysis Inhibitor (TAFI, Plasma Procarboxypeptidase B, Procarboxypeptidase R, Procarboxypeptidase U)
BN Bouma, PF Marx, LO Mosnier, JC Meijers |
Thrombosis Research | 2001 |
|
Activity and Antigen Levels of Thrombin-Activatable Fibrinolysis Inhibitor in Plasma of Patients With Disseminated Intravascular Coagulation
R Watanabe, H Wada, Y Watanabe, M Sakakura, T Nakasaki, Y Mori, M Nishikawa, EC Gabazza, T Nobori, H Shiku |
Thrombosis Research | 2001 |
|
arboxypeptidase U at the Interface Between Coagulation and Fibrinolysis
K Schatteman, F Goossens, J Leurs, R Verkerk, S Scharpé, JJ Michiels, D Hendriks |
Clinical and Applied Thrombosis/Hemostasis | 2001 |
|
The topology of plasminogen binding and activation on the surface of human breast cancer cells
NM Andronicos, M Ranson |
British Journal of Cancer | 2001 |
|
Fibrinolytics and Antifibrinolytics
F Bachmann |
2001 | |
|
Regulation of plasminogen binding to neutrophils
T Herren, TA Burke, M Jardi, J Felez, EF Plow |
Blood | 2001 |
|
Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices
GE Davis, KA Pintar, RS Allen, SA Maxwell |
Journal of cell science | 2001 |
|
Role of Zinc Ions in Activation and Inactivation of Thrombin-Activatable Fibrinolysis Inhibitor
PF Marx, BN Bouma, JC Meijers |
Biochemistry | 2001 |
|
Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled
M Henry, H Aubert, PE Morange, I Nanni, MC Alessi, L Tiret, I Juhan-Vague |
Blood | 2001 |
|
Relationship between soluble thrombomodulin in plasma and coagulation or fibrinolysis in type 2 diabetes
Y Aso, Y Fujiwara, K Tayama, K Takebayashi, T Inukai, Y Takemura |
Clinica Chimica Acta | 2000 |
|
Role of blood coagulation factor XI in downregulation of fibrinolysis
BN Bouma, JC Meijers |
Current Opinion in Hematology | 2000 |
|
Platelets
JN George |
The Lancet | 2000 |
|
Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis
CJ Refino, L DeGuzman, D Schmitt, R Smyth, S Jeet, MT Lipari, D Eaton, S Bunting |
Fibrinolysis and Proteolysis | 2000 |
|
CPR-Total (TAFI and Activated TAFI) Levels in Plasma/Serum of Hemophiliacs
X Guo, N Okada, H Okada |
Microbiology and Immunology | 2000 |
|
Inactivation of Active Thrombin-activable Fibrinolysis Inhibitor Takes Place by a Process That Involves Conformational Instability Rather Than Proteolytic Cleavage
PF Marx, TM Hackeng, PE Dawson, JH Griffin, JC Meijers, BN Bouma |
The Journal of biological chemistry | 2000 |
|
Thrombin Activatable Fibrinolysis Inhibitor and an Antifibrinolytic Pathway
L Bajzar |
Arteriosclerosis, thrombosis, and vascular biology | 2000 |
|
Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors
I Juhan-Vague, JF Renucci, M Grimaux, PE Morange, J Gouvernet, Y Gourmelin, MC Alessi |
Arteriosclerosis, thrombosis, and vascular biology | 2000 |
|
Pro-Carboxypeptidase R is an Acute Phase Protein in the Mouse, Whereas Carboxypeptidase N Is Not
T Sato, T Miwa, H Akatsu, N Matsukawa, K Obata, N Okada, W Campbell, H Okada |
Journal of immunology (Baltimore, Md. : 1950) | 2000 |
|
Increased Serum Levels and Sinusoidal Expression of Thrombomodulin in Acute Liver Damage
M Takatori, S Iwabuchi, S Ro, M Murayama, S Maeyama, T Uchikoshi, M Nakano, H Ishii |
Thrombosis Research | 1999 |
|
A novel approach to arterial thrombolysis
P Klement, P Liao, L Bajzar |
Blood | 1999 |
|
Purification and Characterization of Human Metallocarboxypeptidase Z
EG Novikova, LD Fricker |
Biochemical and Biophysical Research Communications | 1999 |
|
Thrombin Interacts with Thrombomodulin, Protein C, and Thrombin-activatable Fibrinolysis Inhibitor via Specific and Distinct Domains
SW Hall, M Nagashima, L Zhao, J Morser, LL Leung |
The Journal of biological chemistry | 1999 |
|
Plasmin Converts Factor X from Coagulation Zymogen to Fibrinolysis Cofactor
EL Pryzdial, N Lavigne, N Dupuis, GE Kessler |
The Journal of biological chemistry | 1999 |
|
Assay of Procarboxypeptidase U, a Novel Determinant of the Fibrinolytic Cascade, in Human Plasma
KA Schatteman, FJ Goossens, SS Scharpé, HM Neels, DF Hendriks |
Clinical chemistry | 1999 |
|
Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor
MC Minnema, PW Friederich, M Levi, PA von Borne, LO Mosnier, JC Meijers, BJ Biemond, CE Hack, BN Bouma, H Cate |
Journal of Clinical Investigation | 1998 |
|
Human Procarboxypeptidase U, or Thrombin-activable Fibrinolysis Inhibitor, Is a Substrate for Transglutaminases: EVIDENCE FOR TRANSGLUTAMINASE-CATALYZED CROSS-LINKING TO FIBRIN
Z Valnickova, JJ Enghild |
The Journal of biological chemistry | 1998 |
|
A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis Inhibitor
W Wang, MB Boffa, L Bajzar, JB Walker, ME Nesheim |
The Journal of biological chemistry | 1998 |
|
Plasma and Recombinant Thrombin-activable Fibrinolysis Inhibitor (TAFI) and Activated TAFI Compared with Respect to Glycosylation, Thrombin/Thrombomodulin-dependent Activation, Thermal Stability, and Enzymatic Properties
MB Boffa, W Wang, L Bajzar, ME Nesheim |
The Journal of biological chemistry | 1998 |
|
The p11 Subunit of the Annexin II Tetramer Plays a Key Role in the Stimulation of t-PA-Dependent Plasminogen Activation
G Kassam, BH Le, KS Choi, HM Kang, SL Fitzpatrick, P Louie, DM Waisman |
Biochemistry | 1998 |
|
Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis
PA von Borne, L Bajzar, JC Meijers, ME Nesheim, BN Bouma |
Journal of Clinical Investigation | 1997 |
|
Biochemical characterization of the mouse muscle-specific enolase: developmental changes in electrophoretic variants and selective binding to other proteins
T Merkulova, M Lucas, C Jabet, N Lamandé, JD Rouzeau, F Gros, M Lazar, A Keller |
Biochemical Journal | 1997 |
|
Progress in clinical fibrinolysis
JJ Emeis, JH Verheijen, HK Ronday, MP Maat, P Brakman |
Fibrinolysis and Proteolysis | 1997 |
|
The Kinin System
A Schmaier |
The Kinin System | 1997 |
|
The Plasma Carboxypeptidases and the Regulation of the Plasminogen System
EF Plow, K Allampallam, A Redlitz |
Trends in Cardiovascular Medicine | 1997 |
|
On the Mechanism of the Antifibrinolytic Activity of Plasma Carboxypeptidase B
DV Sakharov, EF Plow, DC Rijken |
The Journal of biological chemistry | 1997 |
|
Metabolism of Bradykinin by Peptidases in Health and Disease
Erdös EG, Skidgel RA |
The Kinin System | 1997 |
|
TAFI, or Plasma Procarboxypeptidase B, Couples the Coagulation and Fibrinolytic Cascades through the Thrombin-Thrombomodulin Complex
L Bajzar, J Morser, M Nesheim |
The Journal of biological chemistry | 1996 |
|
Cell-surface Cytokeratin 8 Is the Major Plasminogen Receptor on Breast Cancer Cells and Is Required for the Accelerated Activation of Cell-associated Plasminogen by Tissue-type Plasminogen Activator
TA Hembrough, L Li, SL Gonias |
The Journal of biological chemistry | 1996 |
|
Autoproteolysis or Plasmin-mediated Cleavage of Factor Xaα Exposes a Plasminogen Binding Site and Inhibits Coagulation
EL Pryzdial, GE Kessler |
The Journal of biological chemistry | 1996 |
|
Inducible Carboxypeptidase Activity: A Role in Clot Lysis In Vivo
A Redlitz, FA Nicolini, JL Malycky, EJ Topol, EF Plow |
Circulation | 1996 |
|
Regulation of Angiogenesis
ID Goldberg, EM Rosen |
1996 | |
|
Carboxypeptidases: new regulators of plasminogen activation in vivo?
DJ Loskutoff |
Journal of Clinical Investigation | 1995 |
|
Vascular Endothelium
MA Gimbrone, MI Cybulsky, N Kume, T Collins, N Resnick |
Annals of the New York Academy of Sciences | 1994 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)